

# ENOVA – European Network of Vaccine Adjuvants

Working group participants, STSM opportunities, Training capabilities (update March 2018)

## ENOVA WG participants

WG1	WG2
Maira Aguiar	Maira Aguiar
Zarko Barjaktarovic	Zarko Barjaktarovic
Emiliano Bedini	Emiliano Bedini
Erdal Bedir	Erdal Bedir
Juliette Ben Arous	Juliette Ben Arous
	Rita Berisio
Konstantina Bitchava	Konstantina Bitchava
	Olesja Bondarenko
Ilias Bouzalas	Ilias Bouzalas
Dennis Christensen	Dennis Christensen
Nicolas Collin	Nicolas Collin
Iskra Cvetkovikj	Iskra Cvetkovikj
Peter Delputte	
Sandra Diebold	Sandra Diebold
Alexandre Dobby	
Mert Doskaya	Mert Doskaya
Sebnem Ercelen	Sebnem Ercelen
Ana Falcón	Ana Falcón
Pavol Farkas	

WG1	WG2
Alberto Fernández-Tejada	Alberto Fernández-Tejada
Brankica Filipic	Brankica Filipic
Andrzej Gamian	Andrzej Gamian
Marie Garinot	
Sveinbjorn Gizurarson	Sveinbjorn Gizurarson
Tor Gjøen	
	Maya Guncheva
Ihsan Gursel	Ihsan Gursel
Maria Issagouliantis	Maria Issagouliantis
Ziga Jakopin	Ziga Jakopin
	Lana Kandalajt
Charalampos Kotzamanidis	
Danina Krajisnik	Danina Krajisnik
Ed Lavelle	Ed Lavelle
Maria Lawrenz	Maria Lawrenz
Georg Lipps	Georg Lipps
Dragomira Majhen	Dragomira Majhen
Jose M. Martinez-Costas	Jose M. Martinez-Costas
Siobhán McClean	

WG1	WG2
Jela Milic	Jela Milic
Anita Milicic	
Antonio Molinaro	Antonio Molinaro
Slavcho Mrenoshki	Slavcho Mrenoshki
Cristina Nativi	Cristina Nativi
Pieter Neels	
Thorunn Olafsdottir	
Ivana Pantelic	Ivana Pantelic
Stephane Paul	Stephane Paul
Jacob Pitcovski	Jacob Pitcovski
Camillo Rosano	Camillo Rosano
Snezana Savic	Snezana Savic
Virgil Schijns	Virgil Schijns
Isabelle Schwartz	
Ehud Shahar	Ehud Shahar
Bram Slütter	Bram Slütter
Maja Stankovic	
Artur Summerfield	Artur Summerfield
Lieke Van der Aa	

## ENOVA STSM opportunities

<p><b>Dr Maira Aguiar</b> (mafsantos@fc.ul.pt) NOVA University of Lisbon, Portugal</p>	<p>Basic and Advanced courses in Modeling and Data analysis. Dr Aguiar works on statistical and mathematical problems applied to infectious disease transmission and control. (4-8 weeks)</p>
<p><b>Dr Zarko Barjaktarovic</b> (Zarko.Barjaktarovic@calims.me) Agency for Medicines and Medical Devices, Montenegro</p>	<p>Quality of Biologics - scientific and regulatory aspects. Systems biology approaches for analyses of complex data. Dr Barjaktarovic works on systems biology analysis and is interested in "systems vaccinology". He is also working as Quality Assessor for Biologics including Advanced Therapy Medicinal Products. (1 week)</p>
<p><b>Dr Emiliano Bedini</b> (ebedini@unina.it) University of Napoli Federico II, Italy</p>	<p>Learn how to perform chemical reactions for the fine, tailored modification of MPLA structure and how to characterize the obtained derivatives by standard and advanced spectroscopic and spectrometric techniques (MALDI and ESI mass spectrometry, 1D- and 2D-NMR spectroscopy). (up to 90 days)</p>
<p><b>Dr Rita Berisio</b> (rita.berisio@cnr.it) Institute of Biostructures and Bioimaging, Italy</p>	<p>Structural biology and biochemistry, molecular biology, x-ray crystallography, CD and fluorescence spectroscopies, light scattering. Dr Berisio works on structural biology of molecular systems involved in human infectious diseases, of vaccine candidates and adjuvants. (30-40 days)</p>
<p><b>Dr Olesja Bondarenko</b> (olesja.bondarenko@kbfi.ee) National Institute of Chemical Physics and Biophysics, Estonia</p>	<p>Interactions of immune cells with biomedical relevant nanomaterial (NM). Dr Bondarenko is interested in the potential of NMs to act as vaccine adjuvants by potentiating the response of immune cells. STSM candidate needs to be approved by Dr Bondarenko's institution (on the basis of CV, experience and recommendation letter). (up to 90 days)</p>
<p><b>Dr Dennis Christensen</b> (den@ssi.dk) Statens Serum institute, Denmark</p>	<p>Vaccine formulation and immunological studies. Dr Christensen works on novel vaccine adjuvants and is co-inventor of the CAF01 and CAF09b adjuvants currently in human clinical trials. He is interested in both human and veterinary vaccines and prophylactic as well as therapeutic approaches. (up to 90 days)</p>

<p><b>Dr Nicolas Collin</b> (nicolas.collin@unil.ch) University of Lausanne, Switzerland</p>	<p>Formulation and characterization of adjuvanted vaccines. Dr Collin leads the Vaccine Formulation Laboratory, which acts as platform for adjuvants for the vaccine community, providing access to a wide range of adjuvants and vaccine formulation expertise. Scope of STSM should be discussed prior application. (up to 90 days)</p>
<p><b>Prof Peter Delputte</b> (peter.delputte@uantwerpen.be) University of Antwerp, Belgium</p>	<p>Evaluation of RSV vaccines. Prof Delputte is focusing on basic and applied research in infectious diseases (viruses, bacteria, parasites and fungi). (up to 90 days)</p>
<p><b>Dr Sandra Diebold</b> (sandra.diebold@nibsc.org) NIBSC, United Kingdom</p>	<p>Batch-release work associated with vaccines such as pyrogen testing; generation of reference materials. Dr Diebold works on exploring nucleic acid Toll-like receptor agonist as adjuvants for tumor immunotherapy. (30-90 days)</p>
<p><b>Dr Alexandre Dobby</b> (adobby@wiv-isp.be) <b>Dr Lieke Van der Aa</b> (Lieke.VanderAa@wiv-isp.be) Scientific Institute of Public Health, Belgium</p>	<p>Quality assurance and quality control of Biological products. Depending on the interest of the candidates we can provide training in Regulatory Affairs, Analytical Development and Validation. Together with the service Immunology at the WIV-ISP we may also organize training (theoretical and practical) on the screening of innate responses induced by novel adjuvants (analysis of PAMPs/PRRs interactions, inflammasome activation) using in vitro models. (5-10 days, from 2019)</p>
<p><b>Dr Mert Duskaya</b> (mert.duskaya@ege.edu.tr) Ege University Medical School, Turkey</p>	<p>Adjuvanted DNA vaccine and recombinant protein vaccine development. Dr Duskaya works on vaccination studies in mouse model against infectious diseases (Toxoplasma gondii, Leishmania, FMDV) and breast cancer. He also works on Vaccine antigen discovery using protein microarrays. (up to 90 days)</p>
<p><b>Dr Ana Falcón</b> (afalcon@cnb.csic.es) National Center for Biotechnology (CNB), National Research Council, Spain</p>	<p>Evaluation of improved or new vaccine candidates or adjuvants in in vivo model (mice). Evaluation of innate immune response in cell culture. Dr Falcon is virologist and focuses on pathogenicity factors of influenza virus. (up to 90 days from 2019)</p>
<p><b>Dr Pavol Farkas</b> (chempalo@savba.sk) Slovak Academy of Sciences, Slovakia</p>	<p>Preparation and characterization of carbohydrate-protein conjugates, fluorescent labeling and/or some immunological methods. Depending on the need of the candidate, it is possible to work in more depth on some specific methods. Dr Farkas works on glycoconjugates as potential vaccine candidates and its testing in vivo and in vitro. (7-28 days)</p>

<p><b>Prof Alberto Fernández-Tejada</b> (afernandeztejada@cicbiogune.es) Center for Cooperative Research in Biosciences, Spain</p>	<p>Design, chemical synthesis and immunological evaluation of novel adjuvant molecules. Prof Fernandez-Tejada works on the development of synthetic saponin-based adjuvants and molecular vaccines. (up to 90 days)</p>
<p><b>Prof Sveinbjorn Gizurarson</b> (sveinbj@hi.is) University of Iceland, Iceland</p>	<p>Short practical projects, preferably small MS or a part of a PhD project, where the student can carry out a small study in our laboratory. Prof Gizurarson works in the field of mucosal adjuvants and mucosal vaccinations, with a special focus on understanding how formulation and adjuvants can be used to direct the immune response towards Th2 or Th1 (or Th3) responses. (up to 90 days)</p>
<p><b>Prof Tor Gj�oen</b> (tor.gjoen@farmasi.uio.no) University of Oslo, Norway</p>	<p>In vitro testing of innate immune responses, transcriptomics. The main topic of Prof Gjoen's work is to understand innate immunity better to aid development of better adjuvants for vaccines in aquaculture, with emphasis on viral disease in salmon fish. (30 -60 days)</p>
<p><b>Dr Maya Guncheva</b> (maiag@orgchm.bas.bg) Institute of Organic Chemistry with Centre of Phytochemistry, Bulgaria</p>	<p>Training of work on a particular task. Dr Maya Guncheva works on chemical modification of hemocyanins for obtaining new breast cancer and melanoma cancer vaccines. (30-45 days)</p>
<p><b>Prof Ihsan Gursel</b> (ihsangursel@bilkent.edu.tr) Bilkent University, Turkey</p>	<p>Any adjuvant related training can be offered. Prof Gursel works on molecular and cellular mechanisms of innate sensors and adjuvant innovation as well as development of delivery vehicles for vaccine formulations. (up to 30 days)</p>
<p><b>Dr Maria Issagouliantis</b> (maria.issagouliantis@rsu.lv) Riga Stradins University, Latvia</p>	<p>Delivery of immunogens, DNA immunization, tumor protection experiments (after June 2018), in vivo imaging. Dr Issagouliantis works on naked DNA vaccines against viruses causing chronic human infections, as HIV, HCV, HPV. (6 weeks)</p>
<p><b>Prof Ziga Jakopin</b> (Ziga.Jakopin@ffa.uni-lj.si) University of Ljubljana, Slovenia</p>	<p>Evaluation of a compound library for their NOD1/NOD2/NLRP3 activation capacity; preliminary in vitro/ex vivo immunomodulatory activity (using cell lines, primary cells). (up to 90 days)</p>
<p><b>Prof Lana Kandalajt</b> (lana.kandalajt@chuv.ch) Centre hospitalier universitaire vaudois, Switzerland</p>	<p>Vaccine development. Prof Kandalajt is working on DC vaccines in the clinic and in mouse models. (up to 90 days)</p>

<p><b>Prof Danina Krajsnik</b> (danina@pharmacy.bg.ac.rs) University of Belgrade, Serbia</p>	<p>Techniques of modified silica based materials preparation and characterization e.g. rheological measurements, zeta potential and particle size measurement, thermal analysis, light microscopy and analytical characterization. Prof Krajsnik works on the pharmaceutical application of various natural and modified silica based materials. (30 days)</p>
<p><b>Prof Ed Lavelle</b> (lavellee@tcd.ie) Trinity College Dublin, Ireland</p>	<p>Training in culture and activation of dendritic cells and macrophages and roles of specific signaling pathways. Prof Lavelle works on the mechanism of adjuvant action, innate immunity, and mucosal vaccines. (30-60 days)</p>
<p><b>Prof Georg Lipps</b> (georg.lipps@fhnw.ch) University of Applied Sciences and Arts Northwestern Switzerland (FHNW), Switzerland</p>	<p>Outer membrane vesicles (OMV), protein expression, antigen characterization. Prof Lipps works on OMVs from gram-negative bacteria, which carry PAMPs that might be suitable as adjuvant. (60 days)</p>
<p><b>Dr Dragomira Majhen</b> (dmajhen@irb.hr) Ruder Boskovic Institute, Croatia</p>	<p>Cell and virus culture, virus research, confocal microscopy, standard methods used in molecular and cell biology. Dr Majhen works on adenovirus-based vectors aimed at gene transfer and vaccination. (up to 90 days)</p>
<p><b>Dr Jose M. Martinez-Costas</b> (jose.martinez.costas@usc.es) University of Santiago de Compostela, Spain</p>	<p>Design, production and purification of microspheres containing antigens for vaccination. Dr Martinez-Costas works on the molecular biology of avian reoviruses and on viral muNS protein, responsible for the construction of cytoplasmic viroplasm, for generating low-cost subunit vaccines. (2 weeks - 90 days)</p>
<p><b>Dr Siobhán McClean</b> (siobhan.mcclean@ucd.ie) University College Dublin, Ireland</p>	<p>Proteomic approaches for identification of bacterial proteins involved in host cell adhesion/activation. Dr McClean works on host-pathogen interactions and identification of vaccine antigens to prevent against Gram-negative pathogens. (28-42 days)</p>
<p><b>Prof Jela Milic</b> (jela@pharmacy.bg.ac.rs) University of Belgrade, Serbia</p>	<p>Rheological measurements, dynamic light scattering (zeta potential and particle size measurements), thermal analysis, light microscopy, biopharmaceutical and physicochemical characterization. Prof Milic has experience in vehicles and colloidal carriers, which are or may be vaccine adjuvants/stabilizers, such as: different types of colloidal dispersions, microparticles, and liposomes. (30 days)</p>

<p><b>Dr Anita Milicic</b> (anita.milicic@ndm.ox.ac.uk) University of Oxford, United Kingdom</p>	<p>Introduction to vaccine clinical trials, Phase I or Phase II (challenge) using an adjuvanted (or virus-vectored) vaccine. The candidate would be able to learn about various aspects of clinical trials, sample processing and attend relevant University and Institute seminars. Dr Milicic works in vaccine development against a number of infectious diseases, and prostate cancer. She is the lead for adjuvant formulation at the Jenner Institute. (1-3 weeks)</p>
<p><b>Prof Antonio Molinaro</b> (molinaro@unina.it) University of Napoli Federico II, Italy</p>	<p>Scientific training/work in the lab. Prof Antonio Molinaro works on Glycolipid based Adjuvants. (30-90 days)</p>
<p><b>Prof Cristina Nativi</b> (cristina.nativi@unifi.it) University of Florence, Italy</p>	<p>Glycoconjugation (antigens to carriers/adjuvants). Prof Nativi works in the development of synthetic cancer vaccines. (2-3 month)</p>
<p><b>Dr Ivana Pantelic</b> (ivana.pantelic@pharmacy.bg.ac.rs) <b>Dr Snezana Savic</b> (snexs@pharmacy.bg.ac.rs) University of Belgrade, Serbia</p>	<p>Techniques of nano-dispersed systems preparation, rheological measurements, dynamic light scattering (zeta potential and particle size measurements), thermal analysis (DSC, FTIR), light microscopy, atomic force microscopy (AFM on demand), biopharmaceutical and analytical characterization (e.g. UPLC-MS/MS). Dr Pantelic and Dr Savic work on colloidal drug delivery systems that could also serve as vaccine adjuvants. (30 days)</p>
<p><b>Prof Jacob Pitcovski</b> (jp@migal.org.il) MIGAL, Israel</p>	<p>Cloning, expression, immunological tests. Prof Pitcovski works in vaccine development and is interested in biological adjuvants, e.g. LT of E.COLI and innate immunity inducers. (7-14 days)</p>
<p><b>Dr Ehud Shahar</b> (ehudsha@migal.org.il) MIGAL, Israel</p>	<p>Open to ideas. Dr Shahar work is focused on targeted activation of the innate immune response by using combinations of inducer molecules bound to microparticles. He is interested in finding the optimal inducer combination to induce a tumor hostile microenvironment. (up to 90 days)</p>
<p><b>Prof Artur Summerfield</b> (artur.summerfield@vetsuisse.unibe.ch) University of Bern, Switzerland</p>	<p>Laboratory work. Prof Summerfield works on improving veterinary adjuvants for duration of immunity, on mucosal vaccines, and system immunology approaches to adjuvant research. (up to 90 days)</p>
<p><b>Dr Maria Vono</b> (Maria.Vono@unige.ch) University of Geneva, Switzerland</p>	<p>Methods to characterize innate and adaptive immune responses to vaccine formulations. Dr Vono is interested in vaccine responses in early life, which faces additional challenges due to intrinsic limitations of the immune system in the very young. (5 days)</p>

## ENOVA Training capabilities

<p><b>Dr Maira Aguiar</b> (mafsantos@fc.ul.pt) NOVA University of Lisbon, Portugal</p>	<p>Short courses/ workshop in <b>modeling and data analysis</b>. Dr Aguiar works on statistical and mathematical problems applied to infectious disease transmission and control. (1 week)</p>
<p><b>Dr Zarko Barjaktarovic</b> (Zarko.Barjaktarovic@calims.me) Agency for Medicines and Medical Devices, Montenegro</p>	<p><b>Quality of biologics</b> - scientific and regulatory aspects. (1 week) <b>Systems biology</b> approaches for analyses of complex data. (1 week)</p>
<p><b>Dr Erdal Bedir</b> (erdalbedir@iyte.edu.tr) Izmir Institute of Technology, Turkey</p>	<p><b>Isolation and/or chemical modifications of adjuvant candidates</b> from natural sources, preliminary <b>screenings for adjuvant activity</b>. Dr Bedir works on saponin based immunoadjuvants. (2-3 months, only available at the end of the project)</p>
<p><b>Juliette Ben Arous</b> (juliette.benarous@airliquide.com) Seppic, France</p>	<p>Formulation and characterization of <b>emulsion adjuvants</b> for veterinary and / or human vaccines. (2-3 days, 4-8 participants)</p>
<p><b>Dr Rita Berisio</b> (rita.berisio@cnr.it) Institute of Biostructures and Bioimaging, Italy</p>	<p>Wet lab, computational, complementary skills. Dr Berisio works on <b>structural biology</b> of molecular systems involved in human infectious diseases, of vaccine candidates and adjuvants. (7 days)</p>
<p><b>Dr Olesja Bondarenko</b> (olesja.bondarenko@kbfi.ee) National Institute of Chemical Physics and Biophysics, Estonia</p>	<p><b>Hosting/ organizing of lectures-based course</b> with the local speakers and speakers from ENOVA. (2-4 days, 20-25 people, in 2019 or 2020)</p>
<p><b>Dr Sandra Diebold</b> (sandra.diebold@nibsc.org) NIBSC, United Kingdom</p>	<p><b>Batch release; pyrogen testing assays</b>. Dr Diebold works on exploring nucleic acid Toll-like receptor agonist as adjuvants for tumor immunotherapy. (1 day due to unsuitable location)</p>

<p><b>Dr Alexandre Dobly</b> (adobly@wiv-isp.be)  <b>Dr Lieke Van der Aa</b> (Lieke.VanderAa@wiv-isp.be)  Scientific Institute of Public Health, Belgium</p>	<p><b>Regulatory Workshop.</b> Our service could organize/participate in a workshop to provide a general overview on the registration process and inform on and discuss regulatory guidelines that need to be followed during the development of adjuvant/adjuvanted vaccines, marketing authorisation file submission and post-licensing. (2-3 days)</p>
<p><b>Dr Mert Dorskaya</b> (mert.dorskaya@ege.edu.tr)  Ege University Medical School, Turkey</p>	<p>Dr Dorskaya works on vaccination studies in mouse model against infectious diseases (Toxoplasma gondii, Leishmania, FMDV) and breast cancer. He also works on Vaccine antigen discovery using protein microarrays.</p>
<p><b>Dr Ana Falcón</b> (afalcon@cnb.csic.es)  National Center for Biotechnology (CNB),  National Research Council, Spain</p>	<p>Evaluation of improved or new vaccine candidates or adjuvants in <b>in vivo model</b> (mice). Evaluation of <b>innate immune response in cell culture</b>. (1-2 months, from 2020)</p>
<p><b>Prof Alberto Fernández-Tejada</b>  (afernandeztejada@cicbiogune.es)  Center for Cooperative Research in Biosciences,  Spain</p>	<p>Chemical synthesis and approaches towards <b>saponin-based adjuvants</b>. (1 week)</p>
<p><b>Dr Andrzej Gamian</b> (gamian@iitd.pan.wroc.pl)  Institute of Immunology and Experimental  Therapy, Polish Academy of Sciences, Poland</p>	<p><b>Glycobiology, adjuvant formulations, immunochemical analyses of adjuvants compositions.</b> (1 month)</p>
<p><b>Prof Sveinbjorn Gizurarson</b> (sveinbj@hi.is)  University of Iceland, Iceland</p>	<p><b>Animal models.</b> (1 day lecture and practical training as a part of a larger course)</p>
<p><b>Dr Maya Guncheva</b> (maiag@orgchm.bas.bg)  Institute of Organic Chemistry with Centre of  Phytochemistry, Bulgaria</p>	<p><b>Protein isolation, purification, characterization.</b> Dr Maya Guncheva works on chemical modification of hemocyanins for obtaining new breast cancer and melanoma cancer vaccines. (available at a later stage only)</p>
<p><b>Prof Ihsan Gursel</b> (ihsangursel@bilkent.edu.tr)  Bilkent University, Turkey</p>	<p><b>Formulation development, adjuvant testing, in vivo animal studies.</b> (1-2 weeks)</p>



<p><b>Dr Maria Issagouliantis</b> (maria.issagouliantis@rsu.lv) Riga Stradins University, Latvia</p>	<p><b>DNA immunization.</b> Dr Issagouliantis works on naked DNA vaccines against viruses causing chronic human infections, as HIV, HCV, HPV. (1 month)</p>
<p><b>Prof Danina Krajsnik</b> (danina@pharmacy.bg.ac.rs) University of Belgrade, Serbia</p>	<p>Preparation and characterization of <b>inorganic and modified silica based materials</b> as prospective vaccine adjuvants. (1 week)</p>
<p><b>Prof Georg Lipps</b> (georg.lipps@fhnw.ch) University of Applied Sciences and Arts Northwestern Switzerland (FHNW), Switzerland</p>	<p>Outer membrane vesicles (OMV), protein expression, antigen characterization. Prof Lipps works on OMVs from gram-negative bacteria, which carry PAMPs that might be suitable as adjuvant. (60 days)</p>
<p><b>Dr Maria Lawrenz</b> (maria.lawrenz@vformulation.org) Vaccine Formulation Institute, United Kingdom</p>	<p><b>Theoretical and practical training on adjuvants and vaccine formulation.</b> Various theoretical and practical topics on adjuvant manufacturing, formulation preparation and characterization could be covered. (4-5 days)</p>
<p><b>Dr Jose M. Martinez-Costas</b> (jose.martinez.costas@usc.es) University of Santiago de Compostela, Spain</p>	<p><b>Recombinant protein expression.</b> (2 weeks)</p>
<p><b>Dr Siobhán McClean</b> (siobhan.mcclean@ucd.ie) University College Dublin, Ireland</p>	<p>Contribute to a training school. Dr McClean works on host-pathogen interactions and identification of vaccine antigens to prevent against Gram-negative pathogens.</p>
<p><b>Prof Antonio Molinaro</b> (molinaro@unina.it) <b>Dr Emiliano Bedini</b> (ebedini@unina.it) University of Napoli Federico II, Italy</p>	<p>Synthetic and analytical organic chemistry with focus on <b>glycolipid immune-adjuvant preparation and structural characterization.</b> (1 week)</p>
<p><b>Prof Cristina Nativi</b> (cristina.nativi@unifi.it) University of Florence, Italy</p>	<p><b>Glycosides synthesis and glycosylation</b> of multivalent scaffolds or proteins as carriers or adjuvants (NB: if organized with A. Molinaro, NMR of glycosides could be included). (2 days)</p>

<p><b>Pieter Neels</b> (pieter.neels@vaccine-advice.be) Vaccine Advise, Belgium</p>	<p>Seminars and workshops in <b>regulatory</b> science. (1-2 days)</p>
<p><b>Dr Ivana Pantelic</b> (ivana.pantelic@pharmacy.bg.ac.rs) <b>Dr Snezana Savic</b> (snexs@pharmacy.bg.ac.rs) <b>Prof Jela Milic</b> (jela@pharmacy.bg.ac.rs) University of Belgrade, Serbia</p>	<p>Formulation and preparation/characterization of <b>colloidal delivery systems</b> as prospective vaccine adjuvants. (1 week)</p>
<p><b>Prof Virgil Schijns</b> (schijns.virgil@gmail.com) Wageningen University, The Netherlands</p>	<p>Lectures on <b>vaccine adjuvants mode of action and immunology</b></p>
<p><b>Dr Bram Slütter</b> (b.a.slutter@lacdr.leidenuniv.nl) Leiden University, The Netherlands</p>	<p>Workshops on <b>tolerance, immunogenicity nanoparticle, nano-medicine</b></p>
<p><b>Dr Maja Stankovic</b> (Maja.Stankovic@calims.me) Agency for Medicines and Medical Devices, Montenegro</p>	<p>Post-marketing <b>surveillance of vaccine safety</b> with focus on adjuvants. (3-5 days)</p>